High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort
IL1R1 expression is a candidate marker to identify patients with intermediate-risk cytogenetics acute myeloid leukemia at high risk of relapse who benefit from allogeneic hematopoietic stem cell transplantation in first remission.
Authors
- Sandrine Lacoste
- Guy Sauvageau (ORCID: https://orcid.org/0000-0002-4333-7266)
- Véronique Lisi (ORCID: https://orcid.org/0000-0001-5385-4219)
- Guillaume Richard‐Carpentier (ORCID: https://orcid.org/0000-0001-6452-8814)
- Josée Hébert (ORCID: https://orcid.org/0000-0002-2267-1353)
- Banafsheh Khakipoor
- Miriam Marquis (ORCID: https://orcid.org/0000-0002-8442-2862)
- Vincent‐Philippe Lavallée (ORCID: https://orcid.org/0000-0001-9095-0066)
- Patrick Gendron (ORCID: https://orcid.org/0000-0001-9829-2600)
- Jean-François Spinella (ORCID: https://orcid.org/0000-0003-2492-2897)
- Michael Vladovsky
- François Béliveau (ORCID: https://orcid.org/0000-0001-6324-2363)
- Sébastien Lemieux (ORCID: https://orcid.org/0000-0001-5477-1386)
Institutions
- University of Toronto (CA)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- Princess Margaret Cancer Centre (CA)
- Hôpital Maisonneuve-Rosemont (CA)
- Institute for Research in Immunology and Cancer (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Biomarker Research
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1186/s40364-025-00827-6
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Genome Canada
- Génome Québec
- Government of Canada